FDA May Cut Its Losses In Off-Label Promotion Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Amarin, FDA exploring settlement of Vascepa suit; agency could allow Amarin to proceed with its statements and disclosures rather than risk a difficult appeal to Second Circuit, the same court that handed FDA a loss in Caronia three years ago.